199 related articles for article (PubMed ID: 12975087)
1. [Clinical utility of serous tumoural markers].
Martín Suárez A; Alonso Díaz L; Ordiz Alvarez I; Vázquez J; Vizoso Piñeiro F
Aten Primaria; 2003; 32(4):227-39. PubMed ID: 12975087
[No Abstract] [Full Text] [Related]
2. Two cases of breast carcinoma with osteoclastic giant cells: are the osteoclastic giant cells pro-tumoural differentiation of macrophages?
Shishido-Hara Y; Kurata A; Fujiwara M; Itoh H; Imoto S; Kamma H
Diagn Pathol; 2010 Aug; 5():55. PubMed ID: 20731838
[TBL] [Abstract][Full Text] [Related]
3. Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors.
Alanbay I; Aktürk E; Coksuer H; Ercan CM; Karaşahin E; Dede M; Yenen MC; Ozan H; Dilek S
Eur J Gynaecol Oncol; 2012; 33(1):25-30. PubMed ID: 22439401
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.
Altman AD; Nelson GS; Ghatage P; McIntyre JB; Capper D; Chu P; Nation JG; Karnezis AN; Han G; Kalloger SE; Köbel M
Mod Pathol; 2013 Sep; 26(9):1255-63. PubMed ID: 23558569
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas.
Le Page C; Chung J; Rahimi K; Köbel M; Provencher D; Mes-Masson AM
Curr Drug Targets; 2020; 21(10):974-995. PubMed ID: 31622218
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.
Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA
Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749
[TBL] [Abstract][Full Text] [Related]
8. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
[TBL] [Abstract][Full Text] [Related]
9. Cyst fluid NB/70K concentration and leukocyte esterase: two new markers for differentiating pancreatic serous tumors from pseudocysts.
Yong WH; Southern JF; Pins MR; Warshaw AL; Compton CC; Lewandrowski KB
Pancreas; 1995 May; 10(4):342-6. PubMed ID: 7792290
[TBL] [Abstract][Full Text] [Related]
10. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
Devins KM; Zukerberg L; Watkins JC; Hung YP; Oliva E
Int J Gynecol Pathol; 2023 Mar; 42(2):159-166. PubMed ID: 35512220
[TBL] [Abstract][Full Text] [Related]
11. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Ovarian Tumors with Multidetector Computed Tomography and Tumor Markers: Differentiation of Stage I Serous Borderline Tumors and Stage I Serous Malignant Tumors Presenting as Solid-Cystic Mass.
Yu XP; Liu Y; Jiao JW; Yang HJ; Wang RJ; Zhang S
Med Sci Monit; 2020 Aug; 26():e924497. PubMed ID: 32801292
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
[TBL] [Abstract][Full Text] [Related]
14. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
15. Metabolic markers and HSP60 in chemonaive serous solid ovarian cancer versus ascites.
Hjerpe E; Brage SE; Frostvik Stolt M; Johansson H; Shoshan M; Avall-Lundqvist E
Int J Gynecol Cancer; 2014 Oct; 24(8):1389-94. PubMed ID: 25188891
[TBL] [Abstract][Full Text] [Related]
16. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase.
Sehdev AS; Kurman RJ; Kuhn E; Shih IeM
Mod Pathol; 2010 Jun; 23(6):844-55. PubMed ID: 20228782
[TBL] [Abstract][Full Text] [Related]
17. Epithelial markers to detect occult microinvasion in serous ovarian tumors.
Hanselaar AG; Vooijs GP; Mayall B; Ras-Zeijlmans GJ; Chadha-Ajwani S
Int J Gynecol Pathol; 1993 Jan; 12(1):20-7. PubMed ID: 7678103
[TBL] [Abstract][Full Text] [Related]
18. Autoantibody biomarkers for the detection of serous ovarian cancer.
Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS
Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776
[TBL] [Abstract][Full Text] [Related]
19. Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium.
Lawrenson K; Pakzamir E; Liu B; Lee JM; Delgado MK; Duncan K; Gayther SA; Liu S; Roman L; Mhawech-Fauceglia P
PLoS One; 2015; 10(7):e0130909. PubMed ID: 26132201
[TBL] [Abstract][Full Text] [Related]
20. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
